TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05118997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRAflow
Description: IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRAflow
Description: IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVD
Description: An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
Study: NCT05630443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prone position
Description: Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
Study: NCT05449405

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine Maleate 1% Nasal Spray
Description: Chlorpheniramine Maleate 1% Nasal Spray

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT06336317

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
Study: NCT05495308

Intervention type: PROCEDURE
Intervention: neoadjuvant treatment
Description: We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.

Intervention type: PROCEDURE
Intervention: neoadjuvant treatment
Description: We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
Study: NCT05548972

Intervention type: DEVICE
Group type: OTHER
Intervention: G7 Dual Mobility with Vivacit-E bearing
Description: hip arthroplasty with G7 Dual Mobility Vivacit-E bearing

Intervention type: DEVICE
Group type: OTHER
Intervention: G7 Dual Mobility with Vivacit-E bearing
Description: hip arthroplasty with G7 Dual Mobility Vivacit-E bearing

Intervention type: DEVICE
Group type: OTHER
Intervention: G7 Dual Mobility Longevity bearing
Description: hip arthroplasty with G7 Dual Mobility Longevity bearing

Intervention type: DEVICE
Group type: OTHER
Intervention: G7 Dual Mobility Longevity bearing
Description: hip arthroplasty with G7 Dual Mobility Longevity bearing
Study: NCT05223010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg
Description: will be administered 1 hour before arrival to operating room

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg
Description: will be administered 1 hour before arrival to operating room

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg
Description: will be administered 1 hour before arrival to operating room

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: for anaesthesia induction 3-8 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: for anaesthesia induction 3-8 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: for anaesthesia induction 3-8 MAC
Study: NCT05433649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise intervention with the help of elastic bands was carried out for 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration.
Study: NCT05071586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS LTE Stimulator Device Model 1401
Description: Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
Study: NCT06080542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic
Description: This session will consist of an aerobic training session performed on a cycle ergometer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: This session will consist of a HIIT performed with elastic bands
Study: NCT06161714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
Description: 4% articaine with 1:100,000 epinephrine buccal infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml
Description: 2% Lidocaine with 1:100,000 epinephrine buccal infiltration
Study: NCT01013714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Sympathetic Denervation (CSD)
Description: Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
Study: NCT04754646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Split-face injection of RHA® 4 with a cannula into a single NLF.
Description: RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF.
Description: RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
Study: NCT06520527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata
Description: Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk Walking Exercise
Description: Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination
Description: Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
Study: NCT05204914

Intervention type: DEVICE
Group type: OTHER
Intervention: Supra glottic airway devices
Description: Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
Study: NCT05631938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT04745741

Intervention type: RADIATION
Intervention: IB-positive group
Description: The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
Study: NCT05361967

Intervention type: DEVICE
Intervention: The Tack Endovascular System
Description: The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.

Intervention type: DEVICE
Intervention: The Tack Endovascular System
Description: The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
Study: NCT06132334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise training
Description: Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points.~Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of \>300 mg/dL will not be allowed to exercise that day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
Study: NCT05515133

Intervention type: OTHER
Intervention: stressors
Description: Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
Study: NCT05544591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 Q2W
Description: subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 Q4W
Description: subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
Study: NCT06251271

Intervention type: DEVICE
Intervention: Point-of-Care Ultrasound
Description: Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.

Intervention type: DEVICE
Intervention: Point-of-Care Ultrasound
Description: Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
Study: NCT05631938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT01512316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-Cycloserine
Description: 250mg, one dose, 2hrs prior to fMRI
Study: NCT05837091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Sodium Oxybate
Description: Titrated according to standard of care and continued on stable dose for 3 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour polysomnography
Description: Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nextsense EEG earbuds
Description: Ear buds used to record sleep staging worn for a 24-hours period
Study: NCT05837091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axivity device
Description: Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
Study: NCT01512316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose pill
Description: one dose, 2hrs prior to fmri

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Saliva sample
Description: Buccal cell material will be sampled from all participants on day3

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Saliva sample
Description: Buccal cell material will be sampled from all participants on day3

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Saliva sample
Description: Buccal cell material will be sampled from all participants on day3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional neuroimaging (fMRI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional neuroimaging (fMRI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional neuroimaging (fMRI)
Study: NCT06194162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-weighted blanket
Description: The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication.
Study: NCT06165757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: noise stimulation
Description: Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
Study: NCT04525794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRight DCB
Description: The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
Study: NCT06380452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Permethrin Creme
Description: At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Permethrin Creme
Description: At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
Study: NCT05950880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity shoulder exercise
Description: Exercises that target the rotator cuff muscles using 90% of one repetition maximum only for 5 repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises
Study: NCT04761432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neoGuard
Description: NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
Study: NCT05231525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiTOF
Description: Data collection on the WiTOF monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOFscan
Description: Data collection on the TOFscan monitor
Study: NCT03553511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal vault suspension to the uterosacral ligaments
Description: Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McCall culdoplasty
Description: Vaginal hysterectomy with McCall culdoplasty
Study: NCT04579432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
Study: NCT04900454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DVX201
Description: Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
Study: NCT06050070

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: FMRI with sham controlled feedback
Description: During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMRI with real time feedback
Description: During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
Study: NCT06309823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
Study: NCT06142344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quiremspheres™
Description: The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
Study: NCT04754815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-L1 inhibitor administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-L1 inhibitor administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies